Chronic Kidney Disease Drugs Market, By Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Others), By Route of Administratio

Chronic Kidney Disease Drugs Market, By Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), B-Blockers, Calcium Channel Blockers, Loop Diuretics, Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Others), By Route of Administration (Oral and Parentral), By Indication (Diabetic Nephropathy, Glomerulonephritis, Hypertensive Nephropathy, Polycystic Kidney Disease, Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies , Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin–angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

• This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic kidney disease drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

• By Drug Class
• ACE Inhibitors
• Angiotensin Receptor Blockers (ARBs)
• B-Blockers
• Calcium Channel Blockers
• Loop Diuretics
• Erythropoiesis-Stimulating Agents (ESAs)
• Phosphate Binders
• Others
• By Route of Administration:
• Oral
• Parenteral
• By Indication
• Diabetic Nephropathy
• Glomerulonephritis
• Hypertensive Nephropathy
• Polycystic Kidney Disease
• Other Indications
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
• Key Players Insights
• AstraZeneca
• Amgen Inc.
• Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi
• GlaxoSmithKline plc (GSK)
• AbbVie Inc.
• Keryx Biopharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Reata Pharmaceuticals, Inc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG
• Johnson & Johnson
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Akebia Therapeutics, Inc.